1) Anderson IM, Ferrier IN, Baldwin RC, et al:Evidence-based guidelines for treating depressive disorders with antidepressants:A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343-396, 2008
2) American Psychiatric Association:Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. 2010
3) Bailey JE, Potokar J, Coupland N, et al:The 5-HT3 antagonist ondansetron reduces gastrointestinal side-effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol 9:137-141, 1995
4) Bauer M, Bschor T, Pfenning A, et al:World federation of societies of biological psychiatry(WFSBP)guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67-104, 2007
5) Devane CL:Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. Psychopharmacol Bull(Suppl):S29-S41, 2003
6) Eaddy M, Bramley T, Regan T:Time to antidepressant discontinuation:A comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manag Care Interface 16:22-27, 2003
7) Golden RN, Nemeroff CB, McSorley P, et al:Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 63:577-584, 2002
8) Higuchi T, Hong JP, Jung HY, et al:Paroxetine controlled-release formulation in the treatment of major depressive disorder:A randomized, double-blind, placebo-controlled study in Japan and Korea. Psychiatry Clin Neurosci 65:655-663, 2011
9) Hogan TTP, Awad AG, Eastwood R:A self-report predictive of drug compliance-in schizophrenia:Reliability and descriminative ability. Psychol Med 13:177-183, 1983
10) http://www.gsk-clinicalstudyregister.com/
11) 岩田仲生,木村敏史,藤田信明:本邦における抗うつ薬治療中止の実態と抗うつ薬服用患者を対象としたインターネット調査が示す早期抗うつ薬治療中止の背景要因.新薬と臨床60:1655-1666, 2011
12) 川上憲人,大野裕,宇田英典,他:地域住民における心の健康問題と対策基盤の実態に関する研究:3地区の総合解析結果.平成14年度厚生労働科学研究費補助金(厚生労働科学特別研究事業)心の健康問題と対策基盤の実態に関する研究 分担研究報告書,2003
13) Keene MS, Eaddy MT, Mauch RP, et al:Differences in compliance patterns across the selective serotonin reuptake inhibitors(SSRIs). Curr Med Res Opin 21:1651-1655, 2005
14) Kuper DJ:Long-term treatment of depression. J Clin Psychiatry 52(Suppl):S28-S34, 1991
15) Leon AC, Olfson M, Portera L, et al:Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 27:93-105, 1997
16) Melfi CA, Chawla AJ, Croghan TW, et al:The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55:1128-1132, 1998
17) パキシルCR錠使用成績調査(うつ病・うつ状態に関する調査).グラクソ・スミスクライン株式会社
18) Prakash S, Masand MD:Tolerability and adherence issues in antidepressant therapy. Clin Ther 25:2289-2304, 2003
19) Rapaport MH, Schneider LS, Dunner DL, et al:Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 64:1065-1074, 2003
20) Sawada N, Uchida H, Suzuki T, et al:Persistence and compliance to antidepressant treatment in patients with depression:A chart review. BMC Psychiatry 9:38, 2009
21) 精神医学講座担当者会議監修:気分障害治療治療ガイドライン第2版.医学書院,2010
22) 植村昌平,若松明,納田茂,他:放出制御型選択的セロトニン再取り込み阻害剤paroxetine CR錠の臨床薬物動態試験成績.臨床精神薬理15:749-765, 2012
23) 吉田卓史,大坪天平,土田英人,他:Sheehan Disability Scale(SDISS)日本語版の作成と信頼性および妥当性の検討.臨床精神薬理7:1645-1653, 2004
24) 渡邊衡一郎,竹内啓善,菊池俊暁:飲み心地を重視した統合失調症治療のすすめ.精神科治療学25:335-345, 2010